Product Description
Segesterone acetate is available in the United States in a combination contraceptive vaginal ring (Annovera) that releases segesterone acetate and ethinyl estradiol. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/30371999/)
Mechanisms of Action: GnRH Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Vaginal
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: United States
Approved Indications: None
Known Adverse Events: None
Company: EW Healthcare Partners
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Contraception
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ANNOV3454-3 PMR | P1 |
Completed |
Contraception |
2021-06-08 |
22% |
| ANNOV3454-2 PMR | P1 |
Completed |
Contraception |
2021-01-06 |
22% |